{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T14:52:03Z","timestamp":1779115923104,"version":"3.51.4"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,1,24]],"date-time":"2025-01-24T00:00:00Z","timestamp":1737676800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,1,24]],"date-time":"2025-01-24T00:00:00Z","timestamp":1737676800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pediatr Res"],"published-print":{"date-parts":[[2025,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Systemic lupus erythematosus requires glucocorticoids for management. This study investigates how glucocorticoids influence bone in a SLE mouse model, focusing on bone mineral density (BMD), microstructure, and remodeling markers.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>MRL\/lpr and C57BL\/6 mice were administered dexamethasone or saline as a control for 4-weeks. Bone assessments included analyses of BMD, bone structure, and serum levels of RANKL and OPG.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Dexamethasone decreased BMD and altered cortical and trabecular bone thickness in both MRL\/lpr and C57BL\/6 mice. In C57BL\/6 mice, cortical bone exhibited increased catabolism while trabecular bone showed signs of increased anabolism, whereas MRL\/lpr mice did not show significant changes in bone turnover. Both strains experienced weight loss, with a significant decrease in femur length observed only in C57BL\/6 mice. Dexamethasone exacerbated BMD reduction in MRL\/lpr mice and halted its increase in C57BL\/6 mice. C57BL\/6 mice exhibited notable changes in cortical and trabecular bone structure, while MRL\/lpr mice didn\u2019t. After receiving dexamethasone, both strains showed higher serum RANKL levels, especially in C57BL\/6 mice. OPG decreased in both strains.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>Both glucocorticoids and SLE contribute to abnormal bone remodeling through RANKL\/OPG pathway.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Impact<\/jats:title>\n            <jats:p>\n              <jats:list list-type=\"bullet\">\n                <jats:list-item>\n                  <jats:p>Glucocorticoid (GC) treatment in a mouse model of systemic lupus erythematosus (SLE) leads to significant changes in bone parameters, including decreased bone mineral density (BMD) and alterations in bone structure. Those change are associated with the modulation of RANKL and OPG expression.<\/jats:p>\n                <\/jats:list-item>\n                <jats:list-item>\n                  <jats:p>Both GC and inflammation in SLE contribute to BMD reduction, and GC may have a certain protective effect on bone in the early stage of chronic inflammation.<\/jats:p>\n                <\/jats:list-item>\n                <jats:list-item>\n                  <jats:p>GC can upregulate RANKL expression and downregulate OPG expression in vivo. During a state of chronic inflammation, RANKL expression increases. However, OPG may not exert a significant influence on inflammatory stimulation.<\/jats:p>\n                <\/jats:list-item>\n              <\/jats:list>\n            <\/jats:p>\n          <\/jats:sec>","DOI":"10.1038\/s41390-025-03861-0","type":"journal-article","created":{"date-parts":[[2025,1,24]],"date-time":"2025-01-24T11:29:26Z","timestamp":1737718166000},"page":"1140-1148","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Glucocorticoids on bone remodeling in systemic lupus erythematosus mice"],"prefix":"10.1038","volume":"98","author":[{"given":"Sheng","family":"Hao","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuyun","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaowei","family":"Tong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fangkai","family":"Ding","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Runjie","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dan","family":"Feng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoling","family":"Niu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2197-0781","authenticated-orcid":false,"given":"Wenyan","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,1,24]]},"reference":[{"key":"3861_CR1","doi-asserted-by":"publisher","first-page":"1320","DOI":"10.1177\/09612033231202701","volume":"32","author":"F Ceccarelli","year":"2023","unstructured":"Ceccarelli, F. et al. Fragility fractures in lupus patients: Associated factors and comparison of four fracture risk assessment tools. Lupus 32, 1320\u20131327, (2023).","journal-title":"Lupus"},{"key":"3861_CR2","doi-asserted-by":"crossref","unstructured":"Ramesh, P., Jagadeesan, R., Sekaran, S., Dhanasekaran, A. & Vimalraj, S. Flavonoids: Classification, Function, and Molecular Mechanisms Involved in Bone Remodelling. Front. Endocrinol. 12, 779638 (2021).","DOI":"10.3389\/fendo.2021.779638"},{"key":"3861_CR3","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2023.116832","volume":"174","author":"W Qian","year":"2023","unstructured":"Qian, W. et al. Bone intrinsic material and compositional properties in postmenopausal women diagnosed with long-term Type-1 diabetes. Bone 174, 116832, (2023).","journal-title":"Bone"},{"key":"3861_CR4","doi-asserted-by":"publisher","DOI":"10.3389\/fphys.2023.1177829","volume":"14","author":"A Aguilar","year":"2023","unstructured":"Aguilar, A. et al. Pathophysiology of bone disease in chronic kidney disease: from basics to renal osteodystrophy and osteoporosis. Front. Physiol. 14, 1177829, (2023).","journal-title":"Front. Physiol."},{"key":"3861_CR5","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1007\/s10067-019-04787-9","volume":"39","author":"JJ Tong","year":"2020","unstructured":"Tong, J. J. et al. Prevalence and risk factors associated with vertebral osteoporotic fractures in patients with rheumatoid arthritis. Clin. Rheumatol. 39, 357\u2013364, (2020).","journal-title":"Clin. Rheumatol."},{"key":"3861_CR6","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1186\/s13075-021-02562-3","volume":"23","author":"A Corrado","year":"2021","unstructured":"Corrado, A. et al. Influence of glucocorticoid treatment on trabecular bone score and bone remodeling regulators in early rheumatoid arthritis. Arthritis. Res. Ther. 23, 180, (2021).","journal-title":"Arthritis. Res. Ther."},{"key":"3861_CR7","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1007\/s00774-020-01148-4","volume":"39","author":"JY Xue","year":"2021","unstructured":"Xue, J. Y., Ikegawa, S. & Guo, L. Genetic disorders associated with the RANKL\/OPG\/RANK pathway. J. Bone Min. Metab. 39, 45\u201353, (2021).","journal-title":"J. Bone Min. Metab."},{"key":"3861_CR8","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1186\/s12969-022-00717-3","volume":"20","author":"S Hao","year":"2022","unstructured":"Hao, S. et al. Bone remodeling serum markers in children with systemic lupus erythematosus. Pediatr. Rheumatol. Online J. 20, 54, (2022).","journal-title":"Pediatr. Rheumatol. Online J."},{"key":"3861_CR9","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1191\/0961203305lu2039oa","volume":"14","author":"CC Mok","year":"2005","unstructured":"Mok, C. C., Mak, A. & Ma, K. M. Bone mineral density in postmenopausal Chinese patients with systemic lupus erythematosus. Lupus 14, 106\u2013112, (2005).","journal-title":"Lupus"},{"key":"3861_CR10","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1002\/acr.20568","volume":"64","author":"IE Bultink","year":"2012","unstructured":"Bultink, I. E. Osteoporosis and fractures in systemic lupus erythematosus. Arthritis. Care Res. 64, 2\u20138, (2012).","journal-title":"Arthritis. Care Res."},{"key":"3861_CR11","doi-asserted-by":"publisher","first-page":"1431","DOI":"10.1007\/s00431-020-03910-2","volume":"180","author":"P Jongvilaikasem","year":"2021","unstructured":"Jongvilaikasem, P. & Rianthavorn, P. Longitudinal growth patterns and final height in childhood-onset systemic lupus erythematosus. Eur. J. Pediatr. 180, 1431\u20131441, (2021).","journal-title":"Eur. J. Pediatr."},{"key":"3861_CR12","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1007\/s00296-018-4168-0","volume":"39","author":"ED Batu","year":"2019","unstructured":"Batu, E. D. Glucocorticoid treatment in juvenile idiopathic arthritis. Rheumatol. Int. 39, 13\u201327, (2019).","journal-title":"Rheumatol. Int."},{"key":"3861_CR13","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/s41232-019-0111-3","volume":"40","author":"T Ono","year":"2020","unstructured":"Ono, T., Hayashi, M., Sasaki, F. & Nakashima, T. RANKL biology: bone metabolism, the immune system, and beyond. Inflamm. Regen. 40, 2, (2020).","journal-title":"Inflamm. Regen."},{"key":"3861_CR14","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1016\/S0140-6736(18)32112-3","volume":"393","author":"JE Compston","year":"2019","unstructured":"Compston, J. E., McClung, M. R. & Leslie, W. D. Osteoporosis. Lancet 393, 364\u2013376, (2019).","journal-title":"Lancet"},{"key":"3861_CR15","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1007\/s00223-017-0335-7","volume":"102","author":"M G\u00fcler-Y\u00fcksel","year":"2018","unstructured":"G\u00fcler-Y\u00fcksel, M., Hoes, J. N., Bultink, I. E. M. & Lems, W. F. Glucocorticoids, Inflammation and Bone. Calcif. Tissue Int. 102, 592\u2013606, (2018).","journal-title":"Calcif. Tissue Int."},{"key":"3861_CR16","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1038\/nrendo.2012.89","volume":"8","author":"SL Teitelbaum","year":"2012","unstructured":"Teitelbaum, S. L. Bone: the conundrum of glucocorticoid-induced osteoporosis. Nat. Rev. Endocrinol. 8, 451\u2013452, (2012).","journal-title":"Nat. Rev. Endocrinol."},{"key":"3861_CR17","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1007\/s001980200108","volume":"13","author":"TP van Staa","year":"2002","unstructured":"van Staa, T. P., Leufkens, H. G. & Cooper, C. The epidemiology of corticosteroid-induced osteoporosis: a meta-analysis. Osteoporos. Int. 13, 777\u2013787, (2002).","journal-title":"Osteoporos. Int."},{"key":"3861_CR18","doi-asserted-by":"publisher","first-page":"3224","DOI":"10.1002\/art.11283","volume":"48","author":"TP Van Staa","year":"2003","unstructured":"Van Staa, T. P. et al. Bone density threshold and other predictors of vertebral fracture in patients receiving oral glucocorticoid therapy. Arthritis Rheum. 48, 3224\u20133229, (2003).","journal-title":"Arthritis Rheum."},{"key":"3861_CR19","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.1177\/0961203319867129","volume":"28","author":"R Ali","year":"2019","unstructured":"Ali, R. et al. Serum RANKL, osteoprotegerin (OPG) and RANKL\/OPG ratio in children with systemic lupus erythematosus. Lupus 28, 1233\u20131242, (2019).","journal-title":"Lupus"},{"key":"3861_CR20","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2023.110572","volume":"123","author":"C Ma","year":"2023","unstructured":"Ma, C. et al. Dihydrotanshinone I attenuates estrogen-deficiency bone loss through RANKL-stimulated NF-\u03baB, ERK and NFATc1 signaling pathways. Int. Immunopharmacol. 123, 110572, (2023).","journal-title":"Int. Immunopharmacol."}],"container-title":["Pediatric Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41390-025-03861-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41390-025-03861-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41390-025-03861-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T08:11:42Z","timestamp":1759911102000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41390-025-03861-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,24]]},"references-count":20,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["3861"],"URL":"https:\/\/doi.org\/10.1038\/s41390-025-03861-0","relation":{},"ISSN":["0031-3998","1530-0447"],"issn-type":[{"value":"0031-3998","type":"print"},{"value":"1530-0447","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,24]]},"assertion":[{"value":"5 May 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 December 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 December 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 January 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The studies involving experimentation on animals was reviewed and approved by Institutional Animal Care and Use Committee of Shanghai Children\u2019s Hospital (No. SHCH-IACUC-2021-XMSB-56).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Each author listed on the manuscript has approved the submission of the manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}]}}